CLINICAL_TRIALS
trial_result
· 2023-04-18
Clinical Trial Update: Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer [Phase 2]
Summary
Phase 2 trial of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seagen Inc. | Conditions: Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-04-18